The Patent Finder

Vicuron Pharmaceuticals Inc.

Also on record
Records under this name other than patents Vicuron Pharmaceuticals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Vicuron Pharmaceuticals Inc.

PatentTitleStatus Expires Confidence
US 6,900,175Methods of administering dalbavancin for treatment of bacterial infections
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,655,676Use of amide derivative of GE 2270 factor A3 for the treatment of acne
Formerly held
Term ended
Term ended Oct 22, 2025 · From the USPTO record
Term endedTerm ended Oct 22, 2025From the USPTO record
US 7,317,001Use of Ramoplanin to Treat Diseases Associated with the Use of Antibiotics
Formerly held
Term ended
Term ended Dec 21, 2024 · High confidence
Term endedTerm ended Dec 21, 2024High confidence
US 7,319,088Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
Formerly held
Term ended
Term ended Sep 25, 2024 · From the USPTO record
Term endedTerm ended Sep 25, 2024From the USPTO record
US 7,307,057Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
Formerly held
Term ended
Ended no later than Jul 12, 2024 · From the USPTO record
Term endedEnded no later than Jul 12, 2024From the USPTO record
US 7,351,687Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
Formerly held
Term ended
Ended no later than Jul 12, 2024 · From the USPTO record
Term endedEnded no later than Jul 12, 2024From the USPTO record
US 8,143,212Dalbavancin compositions for treatment of bacterial infections
Formerly held
Term ended
Term ended Jan 12, 2024 · From the USPTO record
Term endedTerm ended Jan 12, 2024From the USPTO record
US 7,115,564Stable pharmaceutical compositions of dalbavancin and methods of administration
Formerly held
Term ended
Term ended Nov 14, 2023 · From the USPTO record
Term endedTerm ended Nov 14, 2023From the USPTO record
US 7,119,061Dalbavancin compositions for treatment of bacterial infections
Formerly held
Term ended
Ended no later than Nov 14, 2023 · From the USPTO record
Term endedEnded no later than Nov 14, 2023From the USPTO record
US 7,169,890Process for the production of ramoplanin-like amide derivatives
Formerly held
Term ended
Term ended Sep 8, 2023 · From the USPTO record
Term endedTerm ended Sep 8, 2023From the USPTO record
10 of 62 patents shown.
Pro members see all 62.
Pro members: see all 62 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited